Sumatriptan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Sumatriptan: From Migraine and Cluster Headache to Migraine with Brainstem Aura
One-Sentence Summary
Sumatriptan is a 5-HT1B/1D agonist originally used for acute treatment of migraine and cluster headache. The TxGNN model predicts it may be useful for migraine with brainstem aura, a migraine subtype. No clinical trials specific to this subtype are registered, and the 18 publications found are general migraine literature, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine, cluster headache, paroxysmal hemicrania, hemicrania continua (taken from the drug's known indications, because the Singapore registration records contain no indication text) |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Sumatriptan is a serotonin 5-HT1B/1D receptor agonist. It is thought to constrict cranial blood vessels and to inhibit the release of vasoactive neuropeptides such as CGRP from trigeminal nerve endings. Both actions are central to migraine pathophysiology. Detailed mechanism data was not available in the data compiled for this report, so this description relies on the published literature and the model's rationale.
Brainstem aura is a migraine subtype, so the link to sumatriptan's established migraine use is plausible. There is also a caution. Triptans have historically been used carefully, or avoided, in migraine with brainstem aura because of theoretical concerns about vasoconstriction. The supporting evidence is therefore indirect. It comes from general migraine studies, and no study specific to this subtype was found.
The literature does include some data on aura more broadly. One 2015 Neurology paper reports reduced sumatriptan efficacy in migraine with aura compared with migraine without aura. This suggests the benefit seen in general migraine cannot simply be assumed for aura subtypes.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura.
Literature Evidence
The 18 publications found are general migraine or sumatriptan papers. None studies brainstem aura directly. The table lists the 10 most relevant, ordered RCT first, then reviews, then other types.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23657930 | 2014 | RCT | Phytother Res | Double-blind trial in 100 patients with acute migraine without aura, comparing ginger with sumatriptan |
| 1313746 | 1992 | RCT | Cephalalgia | Double-blind, placebo-controlled trial of oral sumatriptan 200 mg in acute migraine with aura |
| 25600718 | 2015 | Review | Headache | American Headache Society evidence assessment of acute migraine drug treatments |
| 26628293 | 2016 | Review | Drugs | Sumatriptan/naproxen combination approved for acute migraine with or without aura; phase 3 trials showed benefit over placebo |
| 8536293 | 1995 | Review | Cephalalgia | Critical review of clinical experience with sumatriptan in migraine and cluster headache |
| 38307660 | 2024 | Review | Handb Clin Neurol | Status migrainosus as a complication of migraine with or without aura |
| 25841032 | 2015 | Other | Neurology | Compares sumatriptan outcomes in migraine with aura versus without aura; reports reduced efficacy with aura |
| 8559405 | 1996 | Other | Neurology | Commentary on subcutaneous sumatriptan and the migraine aura |
| 12917936 | 2003 | Other | Cochrane Database Syst Rev | Review of oral sumatriptan for acute migraine (a later version was withdrawn in 2012) |
| 21459461 | 2011 | Other | Trends Pharmacol Sci | Emerging migraine drug targets, including new routes of sumatriptan administration |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN06744P | IMIGRAN INJECTION 6 mg/0.5 ml | Injection |
| SIN13667P | SUMATRAN TABLET 50MG | Tablet |
| SIN17179P | SUMASON TABLETS 50MG | Tablet, film coated |
| SIN08419P | IMIGRAN TABLET 50 mg | Tablet, film coated |
All four registrations are valid single-ingredient products.
Safety Considerations
- Contraindications suggested by the knowledge graph (not package insert text): The knowledge graph links sumatriptan to many cardiovascular and cerebrovascular conditions, including hypertension, coronary artery disease, myocardial infarction, stroke and peripheral vascular disease. It also lists liver disease, kidney disease and epilepsy. These should be confirmed against the official package insert.
- Drug Interactions: 100 interactions were identified, and 20 were reviewed. The main ones are:
- Major: the serotonergic agents dexfenfluramine, fenfluramine, lorcaserin and sibutramine.
- Major: the 5-HT3 antagonists dolasetron, granisetron, ondansetron and palonosetron.
- Moderate: morphine, including its liposomal form.
- Aura-specific caution: Because of the theoretical vasoconstriction concern, use in brainstem aura needs particular care.
The package insert warnings and contraindications from the Singapore regulator were not available for this report. Please refer to the package insert for the full safety profile.
Conclusion and Next Steps
Decision: Hold
Rationale: Sumatriptan has a plausible mechanism for migraine with brainstem aura, but there are no subtype-specific trials. The supporting literature is general migraine data. The cautious historical stance on triptans in this subtype, and the reported reduced efficacy in aura, argue against moving forward without direct evidence. The decision stage for this indication is also still at early screening, with the Singapore package insert safety review outstanding.
To proceed, the following is needed:
- The Singapore package insert warnings and contraindications, to complete the safety screening
- Subtype-specific clinical evidence on brainstem aura, such as case series or a controlled study
- A cardiovascular and cerebrovascular risk assessment for patients with brainstem aura
- Detailed mechanism of action data, to support the mechanistic-link analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.